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BCL-6 encodes a POZ/zinc finger transcriptional repressor that is required for germinal center formation and
may influence apoptosis. Aberrant expression of BCL-6 due to chromosomal translocations is implicated in
certain subtypes of non-Hodgkin’s lymphoma. The POZ domains of BCL-6 and several other POZ proteins
interact with corepressors N-CoR and SMRT. Here we identify and characterize a novel corepressor BCoR
(BCL-6 interacting corepressor), which is expressed ubiquitously in human tissues. BCoR can function as a
corepressor when tethered to DNA and, when overexpressed, can potentiate BCL-6 repression. Specific class I
and II histone deacetylases (HDACs) interact in vivo with BCoR, suggesting that BCoR may functionally link
these two classes of HDACs. Strikingly, BCoR interacts selectively with the POZ domain of BCL-6 but not
with eight other POZ proteins tested, including PLZF. Additionally, interactions between the BCL-6 POZ
domain and SMRT, N-CoR, and BCoR are mutually exclusive. The specificity of the BCL-6/BCoR interaction
suggests that BCoR may have a role in BCL-6-associated lymphomas.
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The BCL-6 gene was originally identified because of its
involvement in chromosomal translocations associated
with non-Hodgkin’s lymphoma (NHL) (Baron et al. 1993;
Kerckaert et al. 1993; Ye et al. 1993; Miki et al. 1994).
These translocations, which juxtapose the intact coding
sequences of BCL-6 to one of a number of different loci,
are believed to result in deregulated BCL-6 expression
(Ye et al. 1995; Chen et al. 1998). This, in turn, is thought
to have a role in lymphomagenesis. BCL-6 rearrange-
ments are found primarily in two common subtypes of
NHL, diffuse large cell and follicular lymphomas, where
rearrangements occur at a frequency of ∼40% and 10%,
respectively (Bastard et al. 1994; Lo Coco et al. 1994;
Otsuki et al. 1995).
BCL-6 has an important role in normal immune re-
sponses and can either promote or inhibit apoptosis, de-
pending on the situation and cell type (Albagli et al.
1999; Kumagai et al. 1999; Yamochi et al. 1999). BCL-6 is
normally expressed in mature B cells and some CD4+ T
cells of the germinal centers, as well as at lower levels in
several other tissues (Cattoretti et al. 1995; Onizuka et
al. 1995; Allman et al. 1996; Bajalica-Lagercrantz et al.
1998). BCL-6-associated lymphomas are thought to have
arisen from these germinal center B cells (Stein and Dal-
lenbach 1992; Alizadeh et al. 2000). Targeted gene dis-
ruption in mice revealed that BCL-6 is required for ger-
minal center formation and T-cell-dependent antibody
responses (Dent et al. 1997; Fukuda et al. 1997; Ye et al.
1997). In addition, BCL-6-deficient mice are prone to in-
flammatory diseases that are thought to result from Th2-
mediated hyperimmune responses (Dent et al. 1997; Ye
et al. 1997).
The BCL-6 gene encodes a 706-amino-acid protein that
functions as a sequence-specific transcriptional repressor
(Deweindt et al. 1995; Chang et al. 1996; Seyfert et al.
1996). It belongs to a subclass of zinc finger proteins that
contain a POZ domain (also called BTB or ZIN domain)
at the amino terminus and Cys2–His2 zinc fingers at the
carboxyl terminus (Numoto et al. 1993; Bardwell and
Treisman 1994; Zollman et al. 1994; Albagli et al. 1995).
The 120-amino-acid POZ domain is an evolutionarily
conserved protein–protein interaction domain that can
mediate both homomeric as well as heteromeric POZ–
POZ interactions (Bardwell and Treisman 1994; Okabe
et al. 1998). The consensus recognition site for BCL-6 has
been determined and resembles that of STAT proteins
(Dent et al. 1997; Ye et al. 1997; Huynh and Bardwell
1998). Consistent with this, the STAT6-responsive im-
munoglobulin germ line  promoter recently was re-
ported to be down-regulated by BCL-6 (Harris et al.
1999).
The POZ domain of BCL-6 is responsible for a large
portion of the repressive function of the protein, al-
though an intervening region between the POZ domain
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and the zinc finger domain can also mediate repression
independently (Albagli et al. 1996; Chang et al. 1996;
Seyfert et al. 1996). We and others have reported that the
BCL-6 POZ domain interacts with corepressors N-CoR
and SMRT, which are associated with a large transcrip-
tional regulatory complex that includes mSIN3 and the
histone deacetylase HDAC1 (Alland et al. 1997; Dhor-
dain et al. 1997, 1998; Heinzel et al. 1997; Nagy et al.
1997; Huynh and Bardwell 1998). This HDAC1 complex
is recruited by several different classes of transcriptional
repressors (for review, see Knoepfler and Eisenman
1999). In the case of BCL-6, self-association of the POZ
domain is required for interactions with N-CoR and
SMRT (Huynh and Bardwell 1998). These corepressors
are capable of interacting with several other POZ do-
main-containing proteins, including PLZF, a transcrip-
tional repressor that is linked to promyelocytic leukemia
(Hong et al. 1997; Huynh and Bardwell 1998; Wong and
Privalsky 1998). Taken together, these results support a
model in which the POZ domain of BCL-6, PLZF, and
some but not all (Deltour et al. 1999) other POZ-contain-
ing repressors recruit N-CoR/SMRT corepressors and
the HDAC1 complex to promoters of their respective
target genes, thereby inducing a repressive chromatin
state through the functions of HDAC1 (David et al. 1998;
Dhordain et al. 1998; Grignani et al. 1998; Lin et al. 1998;
Wong and Privalsky 1998).
To date, multiple mammalian HDACs have been iden-
tified and characterized, and are grouped into two classes
on the basis of sequence homology with yeast HDACs.
The class I HDACs (HDAC1–HDAC3) are related to
yeast RPD3 (Taunton et al. 1996; Yang et al. 1996, 1997),
and the class II HDACs (HDAC4–HDAC7) share homol-
ogy with yeast HDA1 (Fischle et al. 1999; Grozinger et
al. 1999; Miska et al. 1999; Verdel and Khochbin 1999;
Kao et al. 2000). In yeast, RPD3 and HDA1 are function-
ally distinct; they are found in different complexes and
regulate different sets of genes (Rundlett et al. 1996,
1998). Two recent reports revealed that the corepressors
N-CoR and SMRT, which have hitherto been character-
ized as functioning with the class I HDAC1/HDAC2
complex, can also associate with class II HDAC4,
HDAC5, and HDAC7 (Huang et al. 2000; Kao et al.
2000). These results suggest that the two mammalian
HDAC classes are functionally linked, unlike the yeast
HDACs.
We report here the identification of a novel corepres-
sor, BCoR (BCL-6 corepressor), which interacts specifi-
cally with the POZ domain of BCL-6. The BCoR gene
encodes at least two proteins, a long form containing
1721 amino acids (BCoR) and a short form containing
1004 amino acids BCoR-short (BCoR-S). We find that
BCoR, but not BCoR-S, can repress transcription when
tethered to a promoter and can potentiate transcriptional
repression by BCL-6 in a specific manner, which suggests
that BCoR is involved in BCL-6 repression. Additionally,
both forms of BCoR can associate with specific HDACs
of both class I and class II HDACs, which suggests that
histone/protein deacetylation is a mechanism for BCoR-
mediated repression. Finally, we show that the interac-
tions between the BCL-6 POZ domain and SMRT, N-
CoR, and BCoR are mutually exclusive.
Results
Identification of the novel BCL-6-interacting protein
BCoR in a yeast two-hybrid screen
The yeast two-hybrid approach was used to identify pro-
teins that can interact with the amino-terminal two-
thirds of BCL-6, codons 1–418 [POZ long (POZ-L)]. In
addition to corepressors N-CoR and SMRT, described
previously, we also identified several other candidate
BCL-6-interacting proteins that retested positive for in-
teraction with the original bait and not with irrelevant
test baits in yeast (Huynh and Bardwell 1998). In this
study we focused on one of these, A3, as its interaction
with POZ-L was confirmed in multiple protein–protein
interaction assays (see below).
The 1928-bp sequence of the A3 clone contains a
single continuous ORF, indicating that it is a partial
cDNA. Using conventional cloning methodologies
(see Materials and Methods) we obtained two overlap-
ping cDNA clones that extended A3. These two cDNA
clones generate a 5708 bp sequence encoding a complete
1721-amino-acid ORF, which we call BCoR. We also
isolated cDNAs representing an alternatively pro-
cessed variant of BCoR; the predicted ORF encodes a
shorter protein of 1004 amino acids, designated
BCoR-S. BCoR-S shares an amino-terminal sequence
with BCoR that ends at amino acid 999 (Fig. 1A,B). The
sequence of BCoR-S continues beyond this junction
with five more amino acids: VSPPT. Searches of the
available databases reveal that BCoR is a novel protein,
sharing no significant homology with any known pro-
teins, aside from three tandem ankyrin repeats (residues
1428–1527), that are not contained in BCoR-S (Fig. 1A,B).
A related pseudogene is present in the database,
AC012062 (A. Keating, K.D. Huynh, and V.J. Bardwell,
unpubl.).
BCoR is expressed ubiquitously
To determine the expression profile of BCoR, its cDNA
fragment (A3), which was isolated from the yeast two-
hybrid screen, was used as a probe to screen a
multitissue mRNA dot blot. Expression was detected
in all tissues examined (Fig. 1C), including the spleen
and lymph nodes, where BCL-6 expressing mature B
cells are found. Two transcripts of ∼6.5 and 7 kb were
detected in Northern blot analyses of poly(A)+ RNA
from Daudi (a mature B-cell line that expresses BCL-6)
and HeLa cells (data not shown). Both transcripts were
detected by either a probe for the common region of
BCoR and BCoR-S or a probe specific for the unique 3
portion of BCoR, suggesting that there is additional
alternative RNA processing. BCoR-S mRNA was not
detected by Northern analysis but was detected in
both Daudi and HeLa cells using RT–PCR (data not
shown), indicating that BCoR-S mRNA is expressed at
BCoR, a novel BCL-6 corepressor
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Figure 1. Amino acid sequence and tissue distribution of
BCoR. (A) Deduced amino acid sequence of BCoR. The point of
divergence between BCoR and BCoR-S is indicated (); the
three tandem ankyrin repeats are underlined. (B) Schematic dia-
gram of BCoR and BCoR-S. The ankyrin repeats (codons 1428–
1527) and the region corresponding to the yeast two-hybrid-
isolated cDNA clone (A3; codons 112–753) are indicated. ()
The point of divergence between the two proteins. (C) Expres-
sion of BCoR mRNA in various human tissues. A Human RNA
Master Blot (Clontech) was probed with a cDNA fragment de-
rived from A3. Tissue identification grid, courtesy of Clontech.
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significantly lower levels than BCoR mRNA in these cell
lines.
Full-length BCL-6 and BCoR interact in vitro
and in vivo
A coimmunoprecipitation assay was used to test the in-
teractions of full-length BCL-6 and BCoR. To test for in
vitro interactions, myc epitope-tagged BCoR and non-
tagged BCL-6 full-length proteins were synthesized in
vitro and immunoprecipitated with the -myc antibody.
Immunoprecipitated BCoR can coprecipitate full-length
BCL-6 (Fig. 2B, bottom, lane 2). This result indicates that
full-length BCL-6 and BCoR are capable of interacting in
vitro and that the interaction is direct (assuming that a
protein in the rabbit reticulocyte lysate is not bridging
the interaction). To test the interaction of full-length
BCL-6 and BCoR in vivo, total cell extracts from 293
Figure 2. Full-length BCL-6 and BCoR interact in vitro and in vivo, the POZ domain of BCL-6 is both necessary and sufficient for
interaction with BCoR in vitro, and BCL-6 and BCoR colocalize in the nucleus. (A) Structure of the proteins used in B and C. (Solid
oval) The POZ domain; (solid rectangle) zinc fingers. (*) The myc epitope tag. (B) Coimmunoprecipitation of BCL-6 and BCoR in vitro.
Pair-wise combinations of [35S]methionine-labeled nontagged BCL-6 derivatives and myc-tagged BCoR were produced by cotranslation
and immunoprecipitated with the -myc antibody. The immune complexes were recovered and analyzed by SDS-PAGE (10% for lanes
1–5; 17% for lanes 6,7). The intensity of myc–BCoR in lanes 6 and 7 appears stronger due to compression on the 17% gel of
non-full-length myc-BCoR proteins. Input represents 20% of the total used. () The expected migration of the nontagged BCL-6
derivatives. (C) Coimmunoprecipitation of BCL-6 and BCoR in vivo. 293 cells were transfected with 3 µg of BCL-6 expression plasmid
alone (lane 2) or cotransfected with 3 µg each of BCL-6 and myc-tagged BCoR expression plasmids (lanes 1,3). Cell lysates were
immunoprecipitated with -myc antibody (lanes 2,3) and the recovered proteins were detected by Western blot analysis using N-3
-BCL-6 and -myc antibodies. The input (lane 1) corresponds to 1/50 of the lysate used in the immunoprecipitation (lane 3). (D)
Subcellular localization of BCoR and BCoR-S. Immunofluorescence was performed on HeLa cells transfected with 1.2 µg of either
myc-tagged BCoR or BCoR-S expression plasmids. Multiple Z series confocal microscopy images of the given fields were compiled for
each image of BCoR and BCoR-S. (E) Colocalization of BCL-6 and BCoR. Coimmunofluorescence was performed on HeLa cells
cotransfected with 0.6 µg each of BCL-6 and myc-tagged BCoR, and the data collected as in D. The compiled images of BCoR and BCL-6
were merged to detect colocalization.
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cells transiently transfected with constructs encoding
myc-tagged BCoR and nontagged BCL-6 were immuno-
precipitated using -myc antibody. Coprecipitation of
the nontagged BCL-6 was observed when constructs for
both BCL-6 and BCoR were cotransfected (Fig. 2C, lane
3) and not when BCL-6 was transfected alone (Fig. 2C,
lane 2). We conclude from these results that full-length
BCL-6 and BCoR are capable of interacting both in vitro
and in vivo.
BCL-6 interacts with BCoR via the POZ domain
To delineate the minimal region in BCL-6 that is impor-
tant for interaction with BCoR, we made various BCL-6
deletions (Fig. 2A) and tested them for interaction with
BCoR in the in vitro coimmunoprecipitation assay.
These BCL-6 deletions include: zinc fingers (ZnFs
codons 418–706), middle (codons 133–512), POZ-L
(codons 1–418), and POZ-S (POZ short; codons 1–132).
To conduct the experiment, pair-wise combinations of
myc-tagged BCoR and the indicated BCL-6 deletions
were synthesized in vitro and immunoprecipitated with
-myc antibody. Among the BCL-6 deletions tested, only
the POZ domain-containing ones were coprecipitated
with BCoR, with the minimal POZ (POZ-S) being suffi-
cient for coprecipitation (Fig. 2B, bottom, lanes 2–5,7).
Coimmunoprecipitation of the POZ domain was depen-
dent on inclusion of myc–BCoR (data not shown). Iden-
tical results were obtained with BCoR-S (data not
shown). We conclude that the POZ domain of BCL-6 is
both necessary and sufficient for the interaction with
BCoR.
BCL-6 and BCoR colocalize in the nucleus
To determine the subcellular localization of BCoR and
BCoR-S, immunofluorescence was performed on HeLa
cells that were transiently transfected with constructs
encoding myc-tagged BCoR and BCoR-S. BCoR is local-
ized exclusively in the nucleus in a diffuse pattern and in
punctate structures of various sizes (Fig. 2D). Although
BCoR-S is also found in punctate structures, in contrast
to BCoR, these are not restricted to the nucleus but are
found in the cytoplasm as well (Fig. 2D). Because BCL-6
is also found in the nucleus in punctate structures (Cat-
toretti et al. 1995) and can colocalize with N-CoR
(Huynh and Bardwell 1998), we tested whether BCL-6
and BCoR could be found in the same nuclear structures.
In HeLa cells cotransfected with constructs encoding
BCL-6 and myc-tagged BCoR, BCL-6 and BCoR colocal-
ize to small and large punctate structures (Fig. 2E), indi-
cating that they may function or be stored together in
these structures. N-CoR and BCoR also colocalize in
similar punctate nuclear structures (data not shown).
Self-association of the BCL-6 POZ domain is required
for interaction with BCoR
We have shown previously that there is a correlation
between the ability of the BCL-6 POZ domain to self-
associate, to interact with both N-CoR and SMRT, and
to repress transcription (Huynh and Bardwell 1998). To
test whether the interaction between BCL-6 and BCoR is
also dependent on self-association of the BCL-6 POZ do-
main, the mammalian two-hybrid assay was used. In this
assay HeLa cells were transfected with a GAL4-respon-
sive luciferase reporter, along with pair-wise combina-
tions of the bait and activator constructs. The bait con-
structs consisted of the GAL4 DNA-binding domain
(DBD) alone or DBD fused to either the wild-type POZ
domain of BCL-6 (POZ-WT, codons 1–132), or mutants
M1, M2, or M3 (Fig. 3A). Mutants M1 and M3 are defec-
tive in self-association, interaction with corepressors N-
CoR and SMRT, and repression, whereas mutant M2 ex-
hibits wild-type behavior (Huynh and Bardwell 1998).
Recent structural studies of the related PLZF POZ do-
main indicate that M1 and M3 would be predicted to
change amino acids critical in the analagous BCL-6
dimerization interface (Ahmad et al. 1998; Li et al. 1999).
The activator construct consists of the VP16 activation
domain fused to the yeast two-hybrid-isolated cDNA
fragment of BCoR (codons 112–753; VB). Cotransfection
of the DBD, M1, or M3 bait constructs, along with VB,
yielded very little reporter activation. Significant re-
porter activation was detected, however, with both the
POZ-WT and M2 bait constructs (Fig. 3B). These results
suggest that BCoR requires self-association of the POZ
domain of BCL-6.
BCoR interacts specifically with the POZ domain
of BCL-6
Our studies with N-CoR and SMRT revealed that these
corepressors can interact with POZ domains from a va-
riety of different proteins other than BCL-6 (Huynh and
Bardwell 1998). To determine whether this is also true of
BCoR we performed the in vitro coimmunoprecipitation
assay again with the same myc-tagged BCoR protein that
was used in Figure 2B. The nontagged POZ-containing
proteins include full-length forms of human BCL-6,
PLZF, and ZID, murine BAZF, and the Drosophila pro-
teins TTK and GAGA. Of the POZ-containing proteins
tested, only BCL-6 is coprecipitated with myc-tagged
BCoR, suggesting that BCoR interacts specifically with
BCL-6 (Fig. 3C). We have confirmed these results using
mammalian two-hybrid and/or GST pull-down assays,
with which we have also tested human FBI-1, murine
ZF5, and a protein derived from the Drosophila E(var)3-
93D gene (protein A) and found that they also cannot
interact with BCoR (data not shown). Of the nine POZ-
containing proteins tested, BCoR interacts selectively
with the POZ domain of BCL-6. In addition, we have
tested and failed to detect an interaction between BCoR
and TR (thyroid hormone receptor ) in the in vitro
coimmunoprecipitation assay (data not shown), which
suggests that BCoR, unlike N-CoR and SMRT, does not
interact with nuclear hormone receptors.
BCoR is a transcriptional corepressor
Having shown that BCL-6 can interact with BCoR and
BCoR-S, we wanted to determine the functional role of
Huynh et al.
1814 GENES & DEVELOPMENT
these proteins. BCL-6 is a transcriptional repressor,
and the lack of a recognizable DNA-binding domain in
BCoR suggests that BCoR may function as a corepressor.
To test this, we fused the GAL4 DBD to BCoR and
BCoR-S and determined what transcriptional effects
these fusion proteins have on a GAL4-responsive re-
porter gene. The experiment was performed by cotrans-
fecting HeLa cells with an SV40 promoter- and enhancer-
driven, GAL4-responsive luciferase reporter (SV40 Enh
G5), along with constructs for DBD alone or fusions with
BCoR or BCoR-S (Fig. 4A). We find that BCoR harbors a
dose-dependent transcriptional repression activity that
is not seen in BCoR-S or the GAL4 DBD alone (Fig. 4B).
The DBD BCoR fusion has no effect on the reporter
without the GAL4 binding sites (data not shown). At
higher concentrations, BCoR-S has a weak repressive
effect (data not shown; see Discussion). We conclude
from these results that BCoR is a corepressor that can
repress transcription when physically tethered to a
promoter.
Figure 3. Self association of the POZ domain
of BCL-6 is required for interaction with BCoR,
and BCoR interacts selectively with the POZ
domain of BCL-6. (A) Structures of the reporter
construct, bait, and activator proteins used in
B. The bait proteins consist of the GAL4 DBD
alone, or fused to wild type or the indicated
mutant POZ domains. The activator-tagged
protein VB consists of the VP16 activation do-
main fused to the yeast two-hybrid-isolated
BCoR clone (codons 112–753). (B) Interactions
of BCoR (codons 112–753) with BCL-6 POZ do-
main point mutants in the mammalian two-
hybrid assay. Luciferase and -gal assays were
conducted on cell extracts from HeLa cells
transiently transfected with 500 ng of the
GAL4-responsive reporter (pAH205), 50 ng of
the indicated bait expression plasmids; 0, 50, or
250 ng of the VB expression plasmid; and 25 ng
of the pCMVlacZ plasmid, as control for trans-
fection efficiency. Data displayed represent the
average of two experiments with the standard
deviations depicted. (C) In vitro coimmunopre-
cipitation of BCoR and BCoR-S with POZ-con-
taining proteins. The indicated pair-wise com-
binations of [35S]methionine-labeled nontagged
POZ proteins (BCL-6, PLZF, BAZF, ZID, TTK,
and GAGA) and either myc-tagged BCoR or
BCoR-S were produced by cotranslation and
immunoprecipitated with -myc antibody. The
proteins were recovered and analyzed by 8%
SDS-PAGE. () The expected migration of the
nontagged BCL-6 derivatives.
Figure 4. BCoR is a transcriptional core-
pressor. (A) Structures of the reporter con-
struct and proteins used in B. (B) Lucifer-
ase and -gal assays were performed on
cell extracts from HeLa cells transiently
transfected with 50 ng of the GAL4-re-
sponsive reporter (SV40 Enh G5), along
with 0, 5, 10, or 25 ng of the indicated
GAL4 fusion constructs [GAL4 DBD
alone (DBD) or DBD fused with BCoR or
BCoR-S), and 25 ng of pCMVLacZ plas-
mid. Data displayed represent the average
of two experiments, with the standard de-
viations depicted. Fold repression was de-
termined by normalizing luciferase/-gal
values of all samples to that of the reporter
alone.
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BCoR is involved in BCL-6 repression
Having established that BCoR contains transcriptional
repression activity, we sought to determine whether
BCoR is involved in BCL-6 repression. If BCoR is a true
BCL-6 corepressor, it should potentiate BCL-6 repression
when endogenous BCoR is limiting. The experiment was
conducted by cotransfecting HeLa cells with an SV40
promoter- and enhancer-driven luciferase reporter con-
taining five BCL-6 binding sites immediately upstream
of the SV40 promoter (5× BCL-6), along with various
combinations of expression constructs for BCL-6, BCoR,
and BCoR-S (Fig. 5A). The parental reporter lacking
BCL-6 sites (SV40 Enh) was used as a control. We first
transfected HeLa cells with either the 5× BCL-6 or the
SV40 Enh reporter construct alone and assayed for lucif-
erase activity of extracts from transfected cells (Fig. 5, B,
fold repression, C and D, luciferase data; note different
scales in C and D). A two- to threefold repression is ob-
served with the 5× BCL-6 reporter relative to the SV40
Enh reporter (Fig. 5B), presumably because of endog-
enous BCL-6, which has been reported to be expressed in
HeLa cells (Allman et al. 1996). Addition of increasing
amounts of BCoR or BCoR-S with either reporter re-
sulted in no change or weak activation. With additional
BCL-6 expression, repression of the 5× BCL-6 reporter is
increased to a maximum of sixfold. This repression is
further potentiated to 28-fold, in a specific and dose-de-
pendent manner when BCoR, but not BCoR-S, is cotrans-
fected along with BCL-6. To confirm the specificity of
Figure 5. BCoR can selectively potentiate BCL-6 repression. (A) Structures of the reporter constructs and proteins used in B. (B)
Luciferase and -gal assays were conducted on HeLa cell extracts transiently transfected with 250 ng of either the SV40 Enh or 5×
BCL-6 reporter construct, and the indicated combinations of BCL-6 (25 ng), BAZF (25 ng), BCoR (25 and 50 ng), and BCoR-S (25 and
50 ng); pEFLacZ (200 ng) was also included as control for transfection efficiency. Data displayed represent the average of two
experiments with the standard deviations depicted. Fold repression was determined by normalizing luciferase/-gal values (C,D) of all
samples to that of the SV40 Enh reporter alone.
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the potentiation, we tested the effect of BCoR expression
on repression by BAZF, a POZ-containing transcrip-
tional repressor that does not interact with BCoR (Fig.
3C). BAZF shares high sequence homology with BCL-6
in its POZ domain and zinc finger region and can bind
to the BCL-6 recognition site and repress transcription
(Okabe et al. 1998). As expected, we find that overex-
pression of BCoR failed to potentiate BAZF repression
(Fig. 5B), which suggests that potentiation of repression
by BCoR is selective for BCL-6. We conclude that BCoR
is capable of functioning as a BCL-6 corepressor.
BCoR interacts with specific class I and class II
HDACs in vivo
We wanted to address the mechanism of BCoR-mediated
repression. Because HDACs appear to be involved in re-
pression by an increasing number of transcriptional re-
pressors, we tested whether BCoR can associate with
HDACs. Using the in vivo coimmunoprecipitation as-
say, we assayed seven of the known human HDACs; the
class I HDACs, HDAC1 and HDAC3, and the class II
HDACs, HDAC-A/4, HDAC-B/5, HDAC-C, HDAC-D,
and HDAC-E/6 (Fischle et al. 1999; Grozinger et al.
1999; W. Fischle and E. Verdin, unpubl.) for interactions
with BCoR. We transfected 293 cells with pair-wise com-
binations of various Flag-tagged HDAC and myc-tagged
BCoR expression constructs, and immunoprecipitated
the cell extracts with -Flag antibody. BCoR coprecipi-
tates most strongly with HDAC1, HDAC3, and HDAC-
B/5 and more weakly with the other HDACs (Fig. 6A).
We also tested BCoR-S for interactions with these
HDACs and found that in addition to HDAC1, HDAC3,
and HDAC-B/5, it also readily coprecipitates with
HDAC-A/4 (Fig. 6B). These results suggest that class I
and class II HDACs might be involved in BCoR-medi-
ated repression.
Interactions between the BCL-6 POZ domain
and N-CoR, SMRT, and BCoR are mutually exclusive
Because SMRT, N-CoR, and BCoR can all interact with
the POZ domain of BCL-6 (Figs. 2B and 3B; Dhordain et
al. 1997; Huynh and Bardwell 1998; Wong and Privalsky
1998), we wanted to determine whether the interactions
are mutually exclusive. We used a variation of the mam-
malian two-hybrid assay in which we assayed the ability
of the corepressors to compete with their VP16-tagged
counterparts for interactions with the BCL-6 POZ bait
(DBD–POZ, Fig. 7A). If two corepressors can bind simul-
taneously, they should not compete for DBD–POZ bind-
ing. We first determined the amount of VP16-tagged co-
repressor that would yield 80%–90% maximal reporter
activation for a given amount of DBD–POZ bait. In this
context, we added the non-VP16-tagged competitor co-
repressors (Fig. 7A). As expected, each of the corepressors
can compete with its respective VP16-tagged corepressor
for binding to the BCL-6 POZ bait (Fig. 7B). More impor-
tantly, competition is also observed with all combina-
tions of VP16-tagged and nontagged corepressors
(SMRT/N-CoR, SMRT/BCoR, and N-CoR/BCoR). This
competition is dose dependent (data not shown). The
suppression of reporter activation by non-VP16-tagged
corepressors is due to competition with VP16-tagged co-
repressors for binding to the BCL-6 POZ bait and not due
to inhibition of VP16 activity, as these competitor pro-
teins had minimal effect on reporter activation by the
GAL4 DBD VP16 fusion (data not shown). In addition, in
the absence of VP16-tagged corepressors, non-VP16-
tagged corepressors had a weak activating (perhaps domi-
nant-negative) effect on DBD–POZ (Fig. 7B). We con-
clude from these results that the interactions among the
POZ domain of BCL-6 and SMRT, N-CoR, and BCoR are
mutually exclusive.
Discussion
In this study our interest in dissecting the mechanisms
of repression by BCL-6 led us to the identification and
characterization of a novel BCL-6-interacting corepres-
sor, BCoR. Several lines of evidence suggest that the in-
teraction between BCL-6 and BCoR is both specific and
functionally important, that it is mutually exclusive
Figure 6. BCoR and BCoR-S interact with class I and class II
HDACs in vivo. 293 cells were transfected with 4 µg of either
myc-tagged BCoR (A) or BCoR-S (B) expression plasmids alone
(first lane), or cotransfected with pair-wise combinations of 3 µg
of the indicated Flag-tagged HDACs and 3 µg of either myc-
tagged BCoR (A) or BCoR-S (B) expression plasmids (remaining
lanes). Cell lysates were imunoprecipitated with -Flag anti-
body, and the recovered proteins were detected by Western blot
analysis using -myc and -Flag antibodies (shown in B only).
The input corresponds to 1/100 of the lysates used for coimmu-
noprecipitation.
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with N-CoR and SMRT, and that BCoR is a corepressor
that is likely to function by recruiting class I and II
HDACs. First, BCoR and BCL-6 interact in vitro and in
vivo (Fig. 2B,C) and colocalize in vivo (Fig. 2E). Second,
the POZ domain of BCL-6 is both necessary and suffi-
cient for interaction with BCoR (Fig. 2B), whereas the
eight other POZ domain-containing proteins tested do
not interact with BCoR (Fig. 3C; data not shown). Third,
BCoR can compete with N-CoR and SMRT for binding
to the BCL-6 POZ domain (Fig. 7). Fourth, BCoR re-
presses transcription when tethered to a promoter (Fig.
4). Fifth, BCoR can potentiate repression by BCL-6 but
not by BAZF (Fig. 5), a POZ-containing repressor closely
related to BCL-6. Finally, BCoR can interact in vivo with
both class I and class II HDACs (Fig. 6).
BCoR is unrelated to other mammalian proteins in the
databases and also has no apparent orthologs in yeast or
nematodes. This suggests that BCoR, like the corepres-
sors N-CoR and SMRT, may perform functions specific
to higher eukaryotes—in contrast to corepressors such as
Sin3 that are widely conserved among eukaryotes, from
yeast to mammals. The ankyrin repeats of BCoR, which
in other proteins are involved in protein–protein inter-
actions, are not required for interaction with BCL-6 or
the HDACs, raising the possibility that additional com-
ponents of a multiprotein complex interact with BCoR.
Our results suggest that self-association of the POZ
domain of BCL-6 is required for interaction with BCoR
(Fig. 3B). It is possible that the residues mutated are criti-
cal for the direct interaction of BCL-6 with BCoR; how-
ever, this is unlikely because these same mutations af-
fect the association of BCL-6 with N-CoR and SMRT.
POZ domains can associate to form dimers, and there is
structural (Li et al. 1999) and functional data indicating
that POZ domain dimers also can associate to form
higher order multimers. Multimer formation of POZ
proteins is likely to have a role in transcriptional regu-
lation, for example, by functionally coupling dispersed
transcription factor binding sites. The best example of
such a mechanism involves the Drosophila POZ protein
GAGA. POZ–POZ interaction of GAGA bound to mul-
tiple widely spaced sites in a single target promoter can
serve to draw GAGA and its associated DNA sites to-
gether (Espinas et al. 1999; Katsani et al. 1999). If BCL-6
also binds its target genes in this way, BCoR might rec-
ognize a specific interface generated by either dimeriza-
tion or higher order multimerization of the BCL-6 POZ
domain.
In this study we have shown that BCoR interacts with
BCL-6 and potentiates transcriptional repression by
BCL-6 with striking specificity. Of the proteins tested,
only BCL-6 interacts with BCoR. However, BCL-6 has a
more limited tissue distribution than the ubiquitously
expressed BCoR (Fig. 1C), suggesting that BCoR may per-
form additional functions. BCoR is likely to be targeted
to DNA by a specific subset of transcriptional repressors,
much like the corepressors N-CoR and SMRT, which
interact with specific members of multiple transcription
factor families, including some POZ-containing proteins
(Huynh and Bardwell 1998; Knoepfler and Eisenman
1999).
BCoR can interact with HDAC1, HDAC3, and HDAC-
Figure 7. Interactions between the BCL-6 POZ domain and N-CoR, SMRT, and BCoR are mutually exclusive. (A) Structures of the
reporter construct and proteins used in B. (B) Luciferase and -gal assays were performed on HeLa cell extracts transiently transfected
with 250 ng of the GAL4-responsive reporter (pAH205), 2.5 ng of the POZ bait, and the indicated combinations of VP16-tagged (VS,
25 ng; VN, 25 ng; VA, 5 ng) and nontagged (S, N, A, at 100 ng each) corepressor expression plasmids, along with 25 ng of the pCMVlacZ
plasmid. Data displayed represent the average of two experiments with the standard deviations depicted.
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B/5 more strongly than with HDAC-A/4, HDAC-C,
HDAC-D, and HDAC-E. Because these represent
HDACs from both class I and class II, the two mamma-
lian HDAC classes might function together, unlike their
yeast counterparts. This possibility is supported further
by two recent reports demonstrating that both SMRT
and N-CoR, which previously appeared to be associated
only with the class I HDAC1 complex, can also associate
with certain class II HDACs (Huang et al. 2000; Kao et al.
2000). Perhaps higher eukaryotes, through corepressors
N-CoR, SMRT, and BCoR, have evolved in such a way as
to functionally link the two HDAC classes, thus increas-
ing potential regulatory complexity. The tissue distribu-
tion of some of the class II HDACs is quite distinct
(Fischle et al. 1999; Grozinger et al. 1999; Verdel and
Khochbin 1999; Wang et al. 1999). Therefore, BCoR may
interact only with a subset of HDACs in a given tissue,
thus further increasing the potential regulatory complex-
ity.
We also identified an alternatively processed variant of
BCoR, BCoR-S, which is a truncated protein that shares
amino-terminal sequence with BCoR. In HeLa and
Daudi cells BCoR-S mRNA is expressed at levels signifi-
cantly lower than BCoR (data not shown), and the trans-
fected protein is found in both the cytoplasm and the
nucleus in contrast to BCoR, which is exclusively
nuclear (Fig. 2D). BCoR-S is capable of interacting with
BCL-6 and HDACs (HDAC1, HDAC3, HDAC-A/4, and
HDAC-B/5) but represses transcription only weakly
when brought to DNA and does not potentiate BCL-6
repression. Because BCoR-S lacks sequences that are pre-
sent in BCoR, including the ankyrin repeats, it is likely
that these additional sequences are important for gener-
ating a multiprotein complex that is fully functional and
that interaction with HDACs is not sufficient for full
corepressor activity. Alternatively B-CoR-S may be ca-
pable of functioning as a corepressor under specific cir-
cumstances or with different transcription factors. A
third possibility is that BCoR-S, when expressed at
higher levels in specific tissues, might act as an antago-
nist of BCoR function. A final possibility is that the
BCoR-S transcript is an incompletely processed BCoR
mRNA.
At present, it is unclear whether BCoR is a previously
unidentified component of a complex with NCoR/
SMRT or whether it is a component of a distinct com-
plex(es). Like N-CoR and SMRT, BCoR interacts with
the POZ domain of BCL-6, and self-association of the
POZ domain is required for this interaction. Further-
more, the interaction between the BCL-6 POZ domain
and each of these corepressors is mutually exclusive (Fig.
7), indicating that they contact the same or overlapping
sites on the POZ domain or that binding of one alloste-
rically inhibits binding of the others. This result,
coupled with our inability to detect an interaction be-
tween BCoR and N-CoR or mSin3 with the in vivo co-
immunoprecipitation assay, using either transfected or
endogenous proteins (data not shown), suggests the pos-
sibility of a distinct complex. However, it is also possible
that these corepressors are components of the same com-
plex that is recruited by POZ domain multimers, with
each corepressor contacting different POZ dimers. Fur-
ther studies will be needed to determine of which com-
plex(es) BCoR is a component. If the N-CoR/SMRT and
BCoR corepressors occur in distinct complexes, it will be
important to ascertain how the selectivity of BCL-6 is
generated for these different complexes and whether it is
context dependent. Recruitment of SMRT by some
nuclear hormone receptors, as well as by the POZ pro-
tein PLZF, is dependent on tyrosine kinase signaling
(Hong et al. 1998). We speculate that extracellular sig-
naling likewise might regulate the recruitment of com-
plexes by BCL-6. Future elucidation of the functions and
regulated assembly of regulatory complexes recruited by
BCL-6 might have important benefits for the rational
design of therapeutic agents directed against diffuse large
cell lymphoma and follicular lymphoma.
Materials and methods
Plasmids
Construction of plasmids was by standard methods; all struc-
tures were verified by appropriate restriction digest and/or se-
quencing.
Yeast two-hybrid assay
The BCL-6 POZ-L bait construct and the Daudi (a mature B-cell
line that expresses BCL-6) Activator Library (carboxy-terminal
library) were described previously (Huynh and Bardwell 1998).
Coimmunoprecipitations
For in vivo experiments, full-length BCL-6 (codons 1–706), and
amino-terminal myc-tagged BCoR (codons 1–1721) and BCoR-S
(codons 1–1004) were cloned into pEFplink2 (Huynh and
Bardwell 1998). Carboxy-terminal Flag-tagged human HDACs
(HDAC1, HDAC3, HDAC-A/4 (codons 118–1085), HDAC-B/5
(codons 132–1123), HDAC-C, HDAC-D, and HDAC-E/6) were
inserted into pcDNA3.1 (Invitrogen). For in vitro experiments,
all cDNAs used were in T7plink vector (Dalton and Treisman
1992): amino-terminal myc-tagged BCoR (codons 1–1721) and
BCoR-S (codons 1–1004), BCL-6 full-length (codons 1–706),
BCL-6 POZ-L (codons 1–418), BCL-6 POZ-S (codons 1–132),
BCL-6 middle (codons 133–512), BCL-6 zinc fingers (codons
418–706), PLZF (codons 1–673), BAZF (codons 1–474), ZID
(codons 1–424), TTK (codons 1–641), and GAGA (codons 1–519).
Immunofluorescence analyses
Mammalian expression plasmids for BCL-6 and myc-tagged
BCoR and BCoR-S were identical to those used for in vivo im-
munoprecipitation assays.
Mammalian two-hybrid and transcriptional repression
analyses
The Gal4-responsive luciferase reporter (pAH205) and the DBD,
POZ-WT (POZ-S), M1 (L19S), M2 (N23H), and M3 (L25S, R26L)
bait constructs were described previously (Huynh and Bardwell
1998). The yeast two-hybrid-isolated cDNA fragments of B-CoR
(codons 112–753), SMRT (codons 1377–1692), and N-CoR
(codons 1007–2043) [Huynh and Bardwell 1998, current amino
acid numberings are according to NP 006303 (SMRT) and
NP 006302.1 (N-CoR)] were cloned into a pEFplink2 expression
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construct that either contains or lacks a VP16 activation do-
main, to generate the VP16-tagged (VB, VS, and VN) or non-
tagged (B, S, and N) proteins, respectively. Both sets of expres-
sion constructs contain an in-frame SV40 nuclear localization
signal (PKKKRKV). The SV40 Enh (pGL3-Control; Promega) and
the SV40 Enh G5 reporters, as well as the DBD and BCL-6
(codons 1–706) mammalian expression constructs were de-
scribed previously (Huynh and Bardwell 1998). The 5× BCL-6
luciferase reporter was constructed by insertion of five copies of
the oligonucleotide 5-TCGAATTCCTCGAAAGTCGA-3 into
the XhoI site of pGL3-Control vector (oligonucleotide orienta-
tion: − + + + +). BCoR (codons 1–1721) and BCoR-S (codons
1–1004) cDNAs were cloned into the GAL4 DBD construct
(Wilkinson and Towle 1997) to generate GAL4 DBD fusions.
BCoR and BCoR-S expression plasmids for potentiation experi-
ments were the same as those used for in vivo coimmunopre-
cipitation analyses. Full-length BAZF (codons 1–474) was in-
serted into pEFplink2. pEFlacZ and pCMVlacZ, used as controls
for transfection efficiency, were described previously (Huynh
and Bardwell 1998).
Isolation of BCoR cDNAs
The yeast two-hybrid screen using BCL-6 POZ-L bait (codons
1–418) was described previously (Huynh and Bardwell 1998).
The yeast two-hybrid isolated clone of BCoR, A3, which was
isolated once, contains a 1928-bp cDNA. A 5 portion of this
cDNA (721-bp fragment, from the start of the cDNA to the PstI
site) was used as a probe to screen a Lambda-ZAPII human adult
frontal cortex cDNA library (a generous gift of M. Macdonald,
Massachusetts General Hospital, Charlestown, MA). This re-
sulted in the isolation of a 3205-bp cDNA (designated 1a) that
encompasses the entire sequence of A3 but still lacks a trans-
lation stop codon in its predicted ORF. The entire sequence of
this cDNA is shared between BCoR and BCoR-S. Further hy-
bridization screening yielded an overlapping cDNA (3583 bp)
that was combined with 1a to yield the full-length BCoR cDNA.
The full-length BCoR-S cDNA was generated by combining 1a
with an overlapping expressed sequence tag (EST AA806538)
clone obtained from Research Genetics.
Cell culture and transfections
HeLa and 293 cells were maintained in complete (10% fetal calf
serum and 0.1 mg/ml penicillin G/streptomycin) RPMI and
DMEM media, respectively. Transfections of HeLa cells were
done by the liposome-mediated method, using the Tfx-20 re-
agent (Promega). Cells were plated at 2 × 105 cells per well in
six-well plates 1 day prior to transfection. For immunofluores-
cence analyses, cells were plated on coverslips. Each transfec-
tion contained the amounts of expression plasmids as indicated
in the figure legends (Fig. 2D,E; 3A,B; 4; 5; 7), along with 3.6 µl
of Tfx-20 reagent (yielding a 2:1 lipid to DNA ratio) in 1 ml of
serum-free media. The total amount of DNA per transfection
was adjusted to 1.2 µg by inclusion of the appropriate amount of
empty parental expression plasmids to keep expression pro-
moter concentrations constant, and/or a pBluescript (Strata-
gene) based filler plasmid. After a 1 hr incubation at 37°C, 2 ml
of complete media was added. Transfections of 293 (a human
kidney cell line) were done with the calcium phosphate-medi-
ated method, using the Profection Mammalian Transfection
System (Promega). Transfections were done in 60-mm plates,
according to the manufacturer’s instructions, with amounts of
expression constructs as indicated in the figure legends (Fig. 2C;
6). For all transfections, cells were harvested 44-48 hr post-
transfection.
Coimmunoprecipitations
In vivo coimmunoprecipitation assays were performed by trans-
fecting 293 cells with the amounts of expression constructs as
indicated in the figure legends (Fig. 2C; 6). Transfected cells
were washed twice with PBS and lysed in 500 µl of cold immu-
noprecipitation (IP) buffer (PBS, 10% glycerol, 0.5% NP-40, and
a complete protease inhibitor cocktail from Boehringer-Mann-
heim) for 10 min on ice. Lysates were briefly sonicated and
centrifuged for 10 min at 4° C. The supernatants were collected
and immunoprecipitated with either 1 µg of -myc (9E10; Santa
Cruz Biotechnology) or 2 µg of -Flag M2 (Sigma) antibodies.
After a 1 hr incubation at 4°C with rotation, 20 µl of protein
A/G Plus-Agarose slurry (Santa Cruz Biotechnology) was added
and reincubated as above. The immune complexes were then
collected and washed three times with 500 µl of cold IP buffer.
The immunoprecipitated proteins were fractionated on 8%
SDS–polyacrylamide gels and transferred to nitrocellulose.
Western analyses were performed with primary antibodies as
indicated in the figure legends [-BCL-6 (N-3; Santa Cruz Bio-
technology), -myc (9E10), or -Flag M2], according to protocols
provided by Santa Cruz Biotechnology. Proteins were visualized
by ECL (Amersham Pharmacia Biotech). For in vitro coimmu-
noprecipitation experiments, the indicated combinations of
[35S]methionine-labeled proteins were cosynthesized using the
TNT T7 Quick Coupled Transcription/Translation System
(Promega), according to the manufacturer’s instructions. Coim-
munoprecipitation experiments were performed as follows: Five
microliters of the indicated TNT reaction mixture was added to
a 45-µl solution (containing 3 µl of unprogrammed reticulocyte
lysate, 10 µl of 50% protein A slurry, and 32 µl of IP buffer) that
had been preincubated at 4°C. After a 1 hr incubation at 4°C
with rotation, the immune complexes were collected and
washed four times with 500 µl of cold IP buffer. The immuno-
precipitated proteins were fractionated on 8%, 10%, or 17%
SDS–polyacrylamide gels.
Immunofluorescence analyses
Immunofluorescence analyses were performed as described
(Skinner et al. 1997). Antibody incubations were as follows: for
BCoR and BCoR-S immunofluorescence, (1) 9E10 mouse mono-
clonal -myc (1:100), (2) rabbit anti-mouse (1:200), (3) Cy2-con-
jugated goat anti-rabbit (1:300; Jackson ImmunoResearch); for
BCL-6 and BCoR coimmunofluorescence, (1) 9E10 and N-3 rab-
bit -BCL-6 (1:100), (2) Cy2-conjugated goat anti-mouse (Jack-
son ImmunoResearch) and rhodamine-conjugated goat anti-rab-
bit (Accurate Chemical and Scientific), both at 1:300.
Other methods
Expression analysis for BCoR using the Human RNA Master
Blot (Clontech) was performed according to the manufacturer’s
instructions. For reporter gene assays, transfected HeLa cells
were lysed in 100 µl of Reporter Lysis Buffer (Promega). Lucif-
erase and -gal assays were conducted according to protocols
provided by Promega and Clontech, respectively.
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